Financial Performance - The company's operating revenue for the first half of 2020 was ¥135,955,018.58, a decrease of 54.62% compared to ¥299,601,012.35 in the same period last year[23] - The net profit attributable to shareholders was -¥92,352,623.14, representing a decline of 459.98% from ¥25,655,258.83 in the previous year[23] - The net cash flow from operating activities was ¥7,890,268.65, down 78.42% from ¥36,565,676.13 in the same period last year[23] - The basic earnings per share were -¥0.1400, a decrease of 459.90% compared to ¥0.0389 in the previous year[23] - Total assets at the end of the reporting period were ¥3,276,674,822.67, a decrease of 4.02% from ¥3,413,954,103.89 at the end of the previous year[23] - The net assets attributable to shareholders were ¥2,219,554,756.01, down 3.99% from ¥2,311,907,379.15 at the end of the previous year[23] - The operating profit was -¥102,271,341.75, reflecting a decline of 391.28% year-on-year, while the total profit was -¥102,045,018.78, down 394.27%[46] - The company reported a revenue of ¥135,955,018.58 for the first half of 2020, a decrease of 54.62% compared to ¥299,601,012.35 in the same period last year[46] - The revenue from the product "Enjingfu" was ¥47,097,117.90, a decrease of 78.56% compared to ¥219,666,305.16[55] - The revenue from the product "Anfulong" increased by 11.18% to ¥88,857,900.68 from ¥79,925,724.06[55] Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[7] - The company is focusing on research and development of new products and technologies to enhance its market position[6] - The company is focusing on the development of the recombinant human NGF eye drops, which received clinical trial approval in May 2020[46] - The company aims to enhance the market penetration of its product "Enjingfu" by improving sales management and expanding marketing efforts[46] - The company is actively working on the production and marketing of the interferon spray "Jiefu," which has shown rapid growth in sales and market share[46] - The company is focused on diversifying its product offerings to mitigate risks associated with product concentration, which currently affects overall revenue[87] - The company is expanding its CDMO project, which may increase competition and management challenges, but aims to leverage equipment and technology advantages for better supply capabilities[88] Research and Development - The company is focused on developing nerve growth factor series products, cytokine drugs, and peptide drugs, with a commitment to advancing biopharmaceutical technology[33] - The company has invested in R&D platforms and collaborations with universities and research institutions to strengthen its product development capabilities[42] - The company is implementing cost control measures to improve operational efficiency and reduce production costs while ensuring compliance with quality standards[47] Risk Management - The company faced significant risks and has outlined corresponding measures in its report[6] - The company faces significant R&D risks due to the lengthy and costly drug development process, which may impact future profitability if new products fail to gain approval[86] - Environmental risks are increasing due to stricter regulations, and the company aims to improve production technology to reduce environmental costs[87] Corporate Governance - The company has committed to maintaining its independence and protecting the legal rights of minority shareholders[165] - The company has made commitments regarding performance guarantees for the years 2014 to 2017, with minimum net profit targets set at 15,160.38 million CNY for 2014 and increasing annually[96] - The company guarantees to notify and prioritize any business opportunities related to pharmaceutical research and production to the listed company[151] - The company has committed to reducing and regulating related party transactions following the completion of the major asset restructuring[157] Shareholder Relations - The company will hold a shareholders' meeting to approve the repurchase of shares to fulfill compensation obligations within two months after the special audit opinion is issued[121] - The counterparty must notify the company if they encounter significant overdue debts that may affect the implementation of the profit compensation agreement[124] Legal and Regulatory Issues - The company failed to timely fulfill the review procedures and information disclosure obligations for related transactions, leading to public reprimands from the Shenzhen Stock Exchange[175] - The controlling shareholder, Beijing Peking University Weiming Biological Engineering Group Co., Ltd., occupied a total of 922 million yuan of the company's funds from December 2017 to June 2019, which accounted for 33.38% of the company's net assets as of 2018[175] - The company disclosed that the controlling shareholder would use four pharmaceutical technologies and 100% equity of Jilin Weiming Tianren Medicinal Material Technology Development Co., Ltd. to offset the occupied funds and interest totaling 561 million yuan[178] - The net asset value of Jilin Weiming was initially reported as 1.813 billion yuan but was later corrected to 11.49 million yuan, indicating significant discrepancies in information disclosure[178] - The company's half-year financial report for 2020 was not audited[169] - There were no major litigation or arbitration matters during the reporting period[172]

Financial Performance - The company reported a significant increase in revenue, reaching RMB 1.2 billion, representing a growth of 15% year-over-year[24] - The net profit for the year was RMB 150 million, which is a 10% increase compared to the previous year[24] - The company's operating revenue for 2019 was ¥567,637,225.78, a decrease of 14.59% compared to ¥664,593,783.42 in 2018[27] - Net profit attributable to shareholders was ¥63,383,506.76, a significant increase of 161.09% from a loss of ¥95,789,054.12 in 2018[27] - The net profit after deducting non-recurring gains and losses was ¥24,661,070.92, up 122.02% from a loss of ¥88,574,215.51 in the previous year[27] - The company's cash flow from operating activities was ¥48,414,581.64, down 72.25% from ¥174,483,553.81 in 2018[27] - Basic and diluted earnings per share were both ¥0.0961, compared to a loss of ¥0.1452 in 2018, marking a turnaround of 161.09%[27] - The total assets at the end of 2019 were ¥3,413,954,103.89, a decrease of 20.73% from ¥4,298,453,211.03 in 2018[27] - The weighted average return on equity was 2.43%, recovering from -3.33% in 2018[27] - The company reported a significant decline in operational performance compared to the previous year, impacting future funding needs[126] Market Expansion and Strategy - User data showed an increase in active users by 20%, totaling 5 million active users by the end of the year[24] - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share within the next three years[24] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[24] - The company is actively pursuing external growth through mergers and acquisitions to strengthen its core competitiveness[45] - The company plans to enhance market development for its products, including the interferon spray "Jiefu," and aims to expand marketing channels[111] Research and Development - New product development includes a pipeline of three innovative drugs expected to enter clinical trials in 2020[24] - The company has allocated RMB 200 million for research and development in the upcoming fiscal year, a 30% increase from the previous year[24] - The company has established multiple biopharmaceutical research platforms and collaborates with renowned research institutions to improve its R&D capabilities[45] - The number of R&D personnel decreased by 6.48% to 101, while the proportion of R&D personnel increased to 13.15%[81] - The company has increased its focus on the development of new products and technologies, particularly in collaboration with domestic research institutions[80] Compliance and Regulatory Issues - The audit report from Zhongxi CPA indicated a qualified opinion, highlighting certain financial discrepancies that need addressing[5] - The company received a warning letter from the Shandong Securities Regulatory Bureau regarding non-compliance in financial transactions with related parties[27] - The company has committed to avoiding conflicts of interest and ensuring that the controlling shareholders do not engage in competitive activities that could harm the company[164] - The company is focused on maintaining compliance with relevant laws and regulations regarding its operations and transactions[193] Financial Management and Dividends - There are no plans to distribute cash dividends or issue bonus shares for the year[6] - The company did not propose any cash dividend distribution for 2019, maintaining a 0.00% payout ratio[123] - The company has not distributed dividends for the past three years, with the last reported net profit in 2017 being ¥387,745,731.93[123] - The company plans to retain profits for operational needs rather than distribute them to shareholders[126] Asset Management and Investments - The company has committed to not distributing dividends or increasing capital through stock dividends for the 2019 fiscal year[127] - The company completed the acquisition of Jilin Weiming Tianren Traditional Chinese Medicine Technology Development Co., Ltd., with a 100% equity stake obtained on December 13, 2019[71] - The company has established a framework for evaluating the assets of its subsidiaries to ensure fair acquisition pricing[179] - The company has committed to compensating for any economic losses incurred by the listed company due to non-compliance with its commitments[190] Operational Efficiency - The company has implemented new strategies to improve operational efficiency, aiming for a 15% reduction in operational costs by the end of 2020[24] - The company is focusing on deepening the development of nerve growth factors and improving production processes to increase yield and reduce energy consumption[112] - The company aims to complete the trial production of the CDMO Phase I project and explore integrated CDMO processes to enhance profitability[112] Risks and Challenges - The company faces risks from policy changes affecting drug pricing and will strengthen its sales team to enhance competitiveness[113] - The company is addressing R&D risks by optimizing project selection and improving R&D capabilities[115] - The company is committed to improving environmental compliance and reducing costs amid increasing regulatory pressures[115] - The company plans to diversify its product offerings to mitigate risks associated with product concentration in revenue generation[115]

山东未名生物医药股份有限公司 2020 年第一季度报告全文 山东未名生物医药股份有限公司 2020 年第一季度报告 2020 年 04 月 1 山东未名生物医药股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人潘爱华、主管会计工作负责人赖闻博及会计机构负责人(会计主 管人员)房君声明：保证季度报告中财务报表的真实、准确、完整。 2 山东未名生物医药股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-----------------------------------------------------|-------|-------|------------------|-------|-- ...

Financial Performance - Operating revenue for the reporting period was CNY 134,829,771.33, a decrease of 32.29% year-on-year[9]. - Net profit attributable to shareholders increased by 238.11% to CNY 23,664,052.46 compared to the same period last year[9]. - Basic earnings per share rose by 238.68% to CNY 0.0359, while diluted earnings per share also increased by 238.68% to CNY 0.0359[9]. - The company's net profit attributable to shareholders for Q3 2019 was not explicitly stated but can be inferred from the changes in retained earnings and total equity[94]. - The net profit for Q3 2019 was CNY 26,006,095.60, a significant increase from CNY 8,113,025.03 in the same period last year, representing a growth of approximately 220.5%[97]. - The profit attributable to the parent company's shareholders was CNY 23,664,052.46, up from CNY 6,998,878.50 year-over-year, marking a growth of approximately 237.5%[98]. - The total profit for the quarter was CNY 25,628,791.91, compared to CNY 16,780,062.30 in Q3 2018, which is an increase of approximately 53.7%[97]. - The company reported a significant increase in other receivables, rising to CNY 850,783,283.46 from CNY 152,360,691.73 year-on-year, indicating potential cash flow issues[88]. Asset and Liability Management - Total assets at the end of the reporting period decreased by 9.70% to CNY 3,881,504,046.13 compared to the end of the previous year[9]. - The company's current assets totaled CNY 1,872,389,439.90, down from CNY 2,523,421,889.72 in December 2018, indicating a decline of approximately 25.8%[84]. - The total liabilities decreased to CNY 996,934,266.17 from CNY 1,471,423,356.40, reflecting a reduction of about 32.2%[85][86]. - The company's total liabilities were CNY 701,203,010.83, down from CNY 812,709,350.21 at the end of 2018, indicating a reduction in financial obligations[92]. - The total assets amounted to 4,298,453,211.03 CNY, with current assets totaling 2,523,421,889.72 CNY[119]. - The total liabilities reached CNY 812,709,350.21, with current liabilities totaling CNY 19,742,575.51 and non-current liabilities at CNY 792,966,774.70[129]. Cash Flow Analysis - Cash flow from operating activities decreased by 79.45% to CNY 1,865,130.36 compared to the same period last year[9]. - Cash and cash equivalents decreased by 34.25% compared to the beginning of the year, primarily due to the repayment of short-term loans[22]. - Cash inflow from operating activities was 530,757,161.73 CNY, down 18.06% from 647,537,608.59 CNY in the previous period[112]. - Cash outflow from operating activities totaled 492,326,355.24 CNY, resulting in a net cash flow from operating activities of 38,430,806.49 CNY, an increase of 20.56% from 31,946,142.28 CNY[113]. - The ending balance of cash and cash equivalents was 1,016,349,364.07 CNY, down from 1,866,351,505.89 CNY at the beginning of the period[114]. - The total cash and cash equivalents at the end of the period was 94,257,638.89 CNY, down from 927,553,596.64 CNY at the beginning of the period, reflecting a decrease of 833,295,957.75 CNY[117]. Investment and R&D - Research and development expenses increased by 71.11% compared to the previous period, reflecting increased investment in R&D[22]. - Research and development expenses for Q3 2019 were CNY 9,707,206.05, showing a slight decrease from CNY 9,874,969.36 in the previous year[95]. - Investment income increased by 12,723.59% compared to the previous period, primarily due to the recognition of investment income from Beijing Kexing[22]. - The main products include injectable nerve growth factor "Enjingfu" and gene-engineered interferon "Anfulong" focusing on the research, production, and sales of biopharmaceuticals[49]. Shareholder and Corporate Governance - The number of ordinary shareholders at the end of the reporting period was 32,836[12]. - The top ten shareholders held a combined 66.73% of the company's shares, with Beijing Peking University Weiming Biological Engineering Group Co., Ltd. holding 26.73%[13]. - The company committed to avoiding direct or indirect competition with its subsidiaries and will not engage in activities that harm the interests of shareholders[51]. - The controlling shareholder, Beijing Peking University Weiming Biological Engineering Group Co., Ltd., will ensure compliance with commitments to avoid conflicts of interest[49]. - The company is committed to transparency and will notify stakeholders of any potential issues affecting the implementation of the profit compensation agreement[47]. - The company has established a framework to regulate related transactions post-major asset restructuring, aiming to protect the interests of the listed company and minority shareholders[67]. Compliance and Regulatory Matters - The company guarantees strict adherence to Chinese securities regulations in all transactions and commitments made[69]. - The company did not engage in any repurchase transactions during the reporting period[19]. - There were no violations regarding external guarantees during the reporting period[75]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[76]. - The company did not engage in any entrusted financial management activities during the reporting period[77].

山东未名生物医药股份有限公司 2019 年半年度报告全文 山东未名生物医药股份有限公司 2019 年半年度报告 2019 年 08 月 1 山东未名生物医药股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人潘爱华、主管会计工作负责人赖闻博及会计机构负责人(会计主 管人员)房君声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第四节"经营情况讨论与分析" 之"十、公司面临的风险和 应对措施" 部分详细描述了公司经营中可能存在的风险及应对措施，敬请投资 者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 山东未名生物医药股份有限公司 2019 年半年度报告全文 目录 | --- | |------------------------------------------------------------------------------------ ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the year 2018, representing a year-on-year increase of 15%[18] - The net profit attributable to shareholders was 150 million RMB, a decrease of 10% compared to the previous year[18] - The company's operating revenue for 2018 was ¥664,593,783.42, a decrease of 42.83% compared to ¥1,162,416,642.55 in 2017[26] - The net profit attributable to shareholders for 2018 was -¥95,789,054.12, representing a decline of 124.66% from ¥388,411,585.68 in 2017[28] - The overall revenue for the company in 2018 was approximately ¥664.59 million, representing a decrease of 42.83% compared to ¥1.16 billion in 2017[63] - The total profit amounted to -¥83,175,449.73, reflecting a year-on-year decline of 117.86%[55] - The company reported a basic earnings per share of -¥0.1452 for 2018, a decrease of 124.66% from ¥0.5887 in 2017[28] - The weighted average return on net assets was -3.33% in 2018, down from 14.27% in 2017[28] - The company recorded non-operating losses totaling -¥7,214,838.61 in 2018, compared to a gain of ¥6,397,118.03 in 2017[36] Research and Development - The company plans to invest 200 million RMB in R&D for new biopharmaceutical products in 2019[18] - The company has established a comprehensive biological drug research and development system with over 6,000 square meters of R&D facilities[51] - The company reported a total of 12 R&D projects in 2018, with approved funding amounting to ¥603.11 million[56] - The company is focusing on the development of nerve growth factor series products and cytokine drugs, with its main product being the injection of mouse nerve growth factor[42] - The company is committed to fulfilling all promises made in the acquisition report, ensuring transparency and accountability[124] - The company has reported a significant focus on research and development in the biopharmaceutical sector, particularly in gene therapy and diagnostics[169] Market Expansion and Strategy - Future guidance indicates a projected revenue growth of 20% for 2019, targeting 1.44 billion RMB[18] - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2019[18] - A strategic acquisition of a local biotech firm is in progress, expected to enhance product offerings and market reach[18] - The company has formed strategic partnerships with major global companies such as Syngenta and Bayer, enhancing its market presence[48] - The company is focusing on expanding its market presence in private hospitals and outpatient sales in response to changing pharmaceutical policies[62] - The company plans to enhance market development for its products, particularly focusing on the interferon spray "Jiefu" and improving sales management systems[108] - The company is actively expanding its market presence through strategic partnerships and potential mergers and acquisitions[166] Financial Management and Cash Flow - The net cash flow from operating activities in 2018 was ¥74,456,075.43, down 72.54% from ¥271,106,655.26 in 2017[28] - Operating cash inflow for 2018 was CNY 1,187,331,551.83, an increase of 14.45% compared to CNY 1,037,388,720.27 in 2017[80] - Operating cash outflow increased by 45.23% to CNY 1,112,875,476.40 from CNY 766,282,065.01 in the previous year[80] - Net cash flow from investment activities was CNY -613,299,195.82, a 439.16% increase in outflow compared to CNY -113,749,824.33 in 2017[80] - The net increase in cash and cash equivalents was CNY -270,666,616.56, a decline of 125.93% compared to an increase of CNY 1,043,693,212.80 in 2017[83] Dividend Policy - The company has no plans to distribute cash dividends or issue bonus shares for the year[9] - The company did not distribute cash dividends in the reporting period, nor did it issue bonus shares or convert capital reserves into share capital[120] - In the past three years, the cash dividend amount was consistently 0.00, with net profits of -95,789,054.12 in 2018, 388,411,585.68 in 2017, and 417,695,144.79 in 2016[119] - The company has not made any cash dividend distributions in the last three years, reflecting a focus on reinvestment rather than shareholder payouts[120] Challenges and Risks - The company faced challenges due to national healthcare reforms impacting revenue, particularly in the nerve growth factor and interferon markets[62] - The company faces risks related to policy changes, R&D challenges, and environmental regulations, which could impact profitability[109] - The overall pharmaceutical industry has seen a decline in profit growth since 2018, influenced by various external factors[106] Asset Management and Investments - The company’s investment in construction projects increased by 698.17% compared to the end of 2017, primarily due to investments in a biological economy incubator and CMO projects in Hefei[46] - The company has not sold any significant assets during the reporting period[101] - The company has not sold any significant equity during the reporting period[104] - The company strictly adheres to the use of raised funds as per public commitments and disclosures[99] Shareholder Commitments - The company plans to repurchase shares at a total price of RMB 1 per share within one month after the shareholders' meeting approval[154] - The company has established a clear formula for calculating compensation amounts and share quantities in case of unmet performance commitments[133] - The company guarantees to avoid any illegal occupation of its funds, assets, or resources by related parties[193] - The commitment to small shareholders has been fulfilled on time[199]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2018, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders was RMB 150 million, a decrease of 10% compared to the previous year[18]. - The company's operating revenue for 2018 was ¥664,593,783.42, a decrease of 42.83% compared to ¥1,162,416,642.55 in 2017[26]. - The net profit attributable to shareholders for 2018 was -¥95,789,054.12, representing a decline of 124.66% from ¥388,411,585.68 in 2017[28]. - The net cash flow from operating activities decreased by 72.54% to ¥74,456,075.43 in 2018 from ¥271,106,655.26 in 2017[28]. - The total profit amounted to -¥83,175,449.73, reflecting a year-on-year decline of 117.86%[55]. - The company reported a basic earnings per share of -¥0.1452 for 2018, down 124.66% from ¥0.5887 in 2017[28]. - The weighted average return on net assets was -3.33% in 2018, a significant drop from 14.27% in 2017[28]. - The overall revenue for the company in 2018 was approximately ¥664.59 million, representing a 42.83% decrease compared to ¥1.16 billion in 2017[63]. - The company reported a significant decrease in sales volume in the chemical raw materials sector, down 93.33% year-on-year, primarily due to the suspension of operations at a subsidiary[70]. Research and Development - The company plans to invest RMB 200 million in R&D for new biopharmaceutical products in 2019, focusing on innovative therapies[18]. - The company has established a comprehensive biopharmaceutical R&D system with over 6,000 square meters of R&D space and advanced precision instruments[45]. - The company reported a total of 12 R&D projects in 2018, with approved funding amounting to ¥603.11 million[56]. - The company is focusing on developing nerve growth factor series products and cytokine drugs, with its main product being the first approved clinical nerve growth factor drug in the world[42]. - The company aims to deepen the development of nerve growth factors and accelerate the research and clinical trials for new indications, including diabetic foot[109]. - The company acknowledges R&D risks associated with the lengthy and costly drug development process, emphasizing the need for improved R&D capabilities[109]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by 2020[18]. - User data indicates a growth in customer base by 20%, reaching 1 million active users by the end of 2018[18]. - The company is actively exploring external growth through mergers and acquisitions to enhance its core competitiveness[45]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region over the next two years[138]. - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to enhance the company's R&D capabilities and add 500 million RMB in annual revenue[139]. Financial Management and Investments - No cash dividends will be distributed to shareholders for the year 2018, as the company focuses on reinvestment[9]. - The company has committed to significant investments in projects such as the CMO project and potential privatization efforts, indicating a focus on long-term growth[115]. - The company’s investment in construction projects increased by 698.17% compared to the end of 2017, primarily due to investments in a biopharmaceutical incubator and CMO projects[46]. - The company plans to conduct a comprehensive impairment test on its assets, with a potential impact of up to 100 million RMB on its financials if significant impairments are identified[142]. - The company has not declared any cash dividends in the last three years, reflecting a strategy focused on reinvestment rather than shareholder payouts[115]. Operational Challenges - The company faced challenges due to regulatory changes and market conditions, impacting the sales of nerve growth factor and interferon products[61]. - The company is implementing a sales-driven production model, facing challenges from intensified competition and declining sales prices in the market[93]. - Environmental risks are increasing due to stricter regulations, prompting the company to enhance production technology to reduce costs[109]. - The company plans to diversify its product offerings to mitigate risks associated with revenue concentration from a few key products[109]. Corporate Governance and Compliance - The company guarantees compliance with relevant laws and regulations, ensuring the protection of the interests of the company and minority shareholders[188]. - The company has not experienced any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[198]. - The company received a qualified audit opinion from Zhongxi Accounting Firm for its 2018 financial statements, with detailed explanations provided by the board of directors[199]. - There were no changes in accounting policies, estimates, or methods during the reporting period[200].

Financial Performance - The company's revenue for Q1 2019 was ¥126,174,347.60, a decrease of 14.25% compared to ¥147,149,643.83 in the same period last year[9]. - The net profit attributable to shareholders was -¥12,926,715.18, representing a decline of 115.69% from ¥82,372,632.77 in the previous year[9]. - The basic earnings per share were -¥0.0196, a decrease of 115.69% compared to ¥0.1249 in the same period last year[9]. - The diluted earnings per share were also -¥0.0196, reflecting the same decline as basic earnings per share[9]. - The weighted average return on equity was -0.47%, down from 2.84% in the previous year[9]. - The total comprehensive income attributable to the parent company was -12,926,715.18 CNY, compared to 82,372,632.77 CNY in the previous period[136]. - Net profit for Q1 2019 was a loss of CNY 9,779,289.94, compared to a profit of CNY 82,202,345.01 in the previous year, indicating a significant decline[132]. Cash Flow and Assets - The net cash flow from operating activities increased by 19.65% to ¥91,695,907.86, compared to ¥76,636,993.46 in the same period last year[9]. - The total assets at the end of the reporting period were ¥3,972,383,771.58, down 7.59% from ¥4,298,453,211.03 at the end of the previous year[9]. - The cash and cash equivalents decreased to CNY 1,289,304,923.34 from CNY 1,545,695,278.42, representing a decline of about 16.6%[109]. - Current assets totaled CNY 587,355,066.73, down from CNY 1,081,569,769.54, a decrease of 45.4%[122]. - The company's total assets as of March 31, 2019, were CNY 4,900,080,079.40, slightly up from CNY 4,894,328,830.26 at the end of 2018[128]. - The ending balance of cash and cash equivalents was 223,775,136.70, down from 842,163,236.12 at the end of the previous period[156]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,929[12]. - The management emphasized a commitment to maintaining shareholder value through consistent dividend payouts, with a proposed dividend of RMB 0.5 per share[45]. - Minority shareholder profit increased by 1948.3% compared to the same period last year, mainly due to the turnaround of Tianjin Weiming from a slight loss to profit[21]. Operational Changes and Future Plans - The company plans to establish a joint venture to produce and sell various chemical products due to production suspension caused by raw material supply interruption and government land requisition[22]. - The joint venture company completed its business registration and obtained a business license in April 2019[22]. - The company expects a revenue growth of 10% for the next quarter, projecting total revenue of RMB 1.65 billion[45]. - New product launches include a novel peptide drug, which is expected to contribute an additional RMB 300 million in revenue by the end of the year[45]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2021[45]. - A strategic acquisition of a biotech firm was completed, valued at RMB 500 million, aimed at enhancing R&D capabilities[45]. - The company plans to invest RMB 200 million in new technology development over the next two years[45]. Liabilities and Expenses - The total liabilities decreased to CNY 1,155,133,206.89 from CNY 1,471,423,356.40, reflecting a reduction of about 21.4%[115]. - Financial expenses decreased by 61.44% compared to the same period last year, primarily due to an increase in interest income from deposits[21]. - Management expenses decreased to 3,504,357.90 CNY from 5,099,327.67 CNY in the previous period, a reduction of approximately 31.3%[137]. - Research and development expenses for the quarter were CNY 10,366,308.01, up from CNY 7,220,441.16, an increase of 43.0%[129]. Compliance and Governance - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[104]. - There were no violations regarding external guarantees during the reporting period[103]. - The company has committed to maintaining compliance with relevant laws and regulations post-transaction completion[100]. - Related party transactions will be conducted at fair market prices, ensuring compliance with legal and regulatory requirements to protect the interests of the company and minority shareholders[94]. - The company will strictly adhere to the regulations set forth by the China Securities Regulatory Commission and other relevant authorities to ensure lawful procedures in all transactions[96].

1 山东未名生物医药股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 山东未名生物医药股份有限公司 2018 年第三季度报告全文 山东未名生物医药股份有限公司 2018 年第三季度报告 2018 年 10 月 一、主要会计数据和财务指标 所有董事均已出席了审议本次季报的董事会会议。 公司是否需追溯调整或重述以前年度会计数据 公司负责人潘爱华、主管会计工作负责人方言及会计机构负责人(会计主管 人员)陈佳宁声明：保证季度报告中财务报表的真实、准确、完整。 □ 是 √ 否 2 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,270,892,991.13 | | 3,998,439,815.42 | 6.81% | | 归属于上市公司股东的净资产 （元） | 2,870,486,180.18 | | 2,857,893,265.92 | 0. ...

Financial Performance - The company's operating revenue for the first half of 2018 was approximately ¥293.78 million, a decrease of 44.60% compared to ¥530.27 million in the same period last year[17]. - The net profit attributable to shareholders was approximately ¥5.59 million, down 96.84% from ¥176.79 million in the previous year[17]. - The net cash flow from operating activities was approximately ¥22.87 million, representing an 80.01% decline from ¥114.40 million in the same period last year[17]. - The basic earnings per share decreased to ¥0.0085, down 96.85% from ¥0.27 in the previous year[17]. - Operating profit fell to CNY 988,300, down 95.12% year-on-year, while net profit attributable to shareholders was CNY 559,400, a decline of 96.84%[36]. - The company reported a total profit of CNY 10,490,092.93, significantly lower than CNY 203,852,449.20 in the previous year, indicating a decline of approximately 94.9%[171]. - The profit attributable to the parent company's shareholders was CNY 5,594,035.76, down from CNY 176,792,824.64, a decrease of about 96.8%[172]. - The company reported a significant decline in domestic customer revenue, totaling approximately ¥291.82 million, down 39.94% year-over-year, with a gross margin of 82.91%[44]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.30 billion, an increase of 7.55% from ¥3.99 billion at the end of the previous year[17]. - The total liabilities amounted to CNY 1,376,966,536.23, up from CNY 1,078,853,139.30, marking an increase of about 27.7%[163]. - Owner's equity totaled CNY 2,923,415,183.20, slightly up from CNY 2,919,586,676.12, showing a marginal increase of about 0.1%[164]. - The company's cash and cash equivalents amounted to approximately ¥1.85 billion, accounting for 43.02% of total assets, an increase from 30.50% in the previous year[47]. - The company's current ratio decreased to 486.48% from 1,051.87%, a decline of 565.39%[152]. - The debt-to-asset ratio increased to 32.02% from 26.98%, an increase of 5.04%[152]. Operational Challenges - The full subsidiary Shandong Weiming Tianyuan Biotechnology Co., Ltd. has been fully suspended since May 8, 2018, leading to a significant decline in revenue and profit[6]. - The company faces various operational risks, which are detailed in the report, and investors are advised to read the risk management section carefully[6]. - The decline in performance is primarily attributed to the suspension of Tianyuan and the inability to obtain financial statements from Beijing Kexing Biological Products Co., Ltd. for calculating investment income[70]. - The company is actively seeking suitable relocation sites for its wholly-owned subsidiary, Shandong Weiming Tianyuan, which has been suspended since May 2018[37]. - The company has faced management issues at Beijing Kexing, leading to a lack of timely financial data and potential audit challenges[97]. Research and Development - The company has established a comprehensive biopharmaceutical R&D system with over 6,000 square meters of R&D facilities and advanced imported equipment[28]. - The company is focusing on deepening the development of nerve growth factor products, aiming to improve yield and reduce energy consumption per unit product[37]. - The biopharmaceutical industry is experiencing a shift towards innovation, with the company focusing on high-quality drug development amidst tightening regulations on generic drugs[27]. - The company plans to accelerate the development of new indications and formulations for nerve growth factor products, including eye drops and water injections[37]. Market Position and Strategy - The company is positioned among the top 30 biopharmaceutical companies in China, reflecting its significant market presence and competitive advantage[30]. - The company has formed strategic partnerships with major global companies such as Syngenta and Bayer, enhancing its market position[32]. - The company is focusing on mergers and acquisitions in the fields of cytokines, peptides, and antibody drugs to enrich its product portfolio[37]. - The company plans to enhance market share for key products, accelerate new product launches, and explore acquisitions and collaborations to diversify its product range[73]. Compliance and Governance - The company is committed to fulfilling its promises regarding avoiding competition and related party transactions as part of its restructuring efforts[79]. - The company guarantees that it and its controlled subsidiaries will not engage in any business that directly or indirectly competes with the listed company[81]. - The company has made commitments to avoid illegal use of funds and resources from its subsidiaries[91]. - The company has pledged to comply with all relevant laws and regulations regarding related party transactions[90]. Cash Flow and Financing - The company reported a cash balance of approximately 1.85 billion RMB at the end of the reporting period, up from 1.82 billion RMB at the beginning[161]. - Cash inflow from financing activities amounted to ¥350,000,000.00, with a net cash flow of ¥339,270,190.30 after outflows[180]. - The company’s liquidity indicators, such as the quick ratio, also saw a significant decline to 477.49% from 1,028.48%[152]. - The company reported a significant increase in cash received from other operating activities, totaling ¥43,211,386.23, compared to ¥6,873,210.83 in the previous period[179]. Environmental and Regulatory Issues - The company is classified as a key pollutant discharge unit by environmental protection authorities[123]. - The company has installed online monitoring devices for wastewater discharge and uploads data to the local environmental authority[125]. - Environmental risks are increasing as regulatory scrutiny intensifies, necessitating improvements in production technology to reduce environmental costs[72]. Shareholder Information - The total number of shares after the recent changes is 659,735,500, with 39.25% being limited shares and 60.75% being unrestricted shares[131]. - The largest shareholder, Beijing Peking University Unnamed Biological Engineering Group Co., Ltd., holds 26.94% of the shares, totaling 177,716,500 shares[135]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[136].